197 0 Kommentare STRATA Skin Sciences Surpasses 100 Domestic Installations of TheraClearX Devices as of March 31, 2024

HORSHAM, Pa., May 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its installed base of TheraClearX devices surpassed 100 at the end of the first quarter of 2024.

As Strata is focused on expanding its TheraClearX placements within existing XTRAC partner clinics, a number of the device placements are with private equity-backed dermatology clinics, including the California Skin Institute and Aqua Dermatology, and other strategic accounts, including Pennsylvania Dermatology Partners, which has 35 clinics in its group practice. Additionally, one device placement was a comeback win with Palo Alto Medical Foundation.

The 48 individual private equity backed groups of clinical dermatology clinics STRATA is currently partnered with have a total of 2,482 locations, in which Strata has deployed 386 XTRAC and 62 TheraClearX devices.

“We continue to grow our domestic installed base of TheraClearX devices quarter by quarter,” commented STRATA CEO Dr. Dolev Rafaeli. “As with our much more established XTRAC offering, dermatologists recognize the value of our comprehensive program in treating acne, which is the most common skin condition in dermatology. TheraClearX addresses many of the limitations of existing acne therapies, and its effectiveness is often visible after just a few treatments. Its unique photo pneumatic technology combines vacuum with pulsed broadband light that works both mechanically and thermally on the active acne lesion. With TheraClearX, dermatologists now have a reimbursable option to treat acne, improving the economics for their practice. We look forward to working closely with our customers/partners to continue to increase our domestic install base and reporting on those outcomes in the coming quarters.”

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.